J 2021

Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance

FOJTŮ, Michaela, Jan BALVAN, Tomáš VIČAR, Hana HOLCOVÁ POLANSKÁ, Barbora PELTANOVÁ et. al.

Basic information

Original name

Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance

Authors

FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution), Tomáš VIČAR (203 Czech Republic, belonging to the institution), Hana HOLCOVÁ POLANSKÁ (203 Czech Republic, belonging to the institution), Barbora PELTANOVÁ (203 Czech Republic, belonging to the institution), Stanislava MATEJKOVA (203 Czech Republic), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Jiri STURALA (203 Czech Republic), Paula MAYORGA-BURREZO, Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and Martin PUMERA (203 Czech Republic, guarantor)

Edition

ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2021, 1944-8244

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

21001 Nano-materials

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 10.383

RIV identification code

RIV/00216224:14110/21:00120131

Organization unit

Faculty of Medicine

UT WoS

000674333400004

Keywords in English

2D nanomaterials; silicene; polysiloxane; nanosheets; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance

Tags

International impact, Reviewed
Změněno: 7/2/2022 12:48, Mgr. Tereza Miškechová

Abstract

V originále

The development of cancer resistance continues to represent a bottleneck of cancer therapy. It is one of the leading factors preventing drugs to exhibit their full therapeutic potential. Consequently, it reduces the efficacy of anticancer therapy and causes the survival rate of therapy-resistant patients to be far from satisfactory. Here, an emerging strategy for overcoming drug resistance is proposed employing a novel two-dimensional (2D) nanomaterial polysiloxane (PSX). We have reported on the synthesis of PSX nanosheets (PSX NSs) and proved that they have favorable properties for biomedical applications. PSX NSs evinced unprecedented cytocompatibility up to the concentration of 300 mu g/mL, while inducing very low level of red blood cell hemolysis and were found to be highly effective for anticancer drug binding. PSX NSs enhanced the efficacy of the anticancer drug doxorubicin (DOX) by around 27.8-43.4% on average and, interestingly, were found to be especially effective in the therapy of drug-resistant tumors, improving the effectiveness of up to 52%. Fluorescence microscopy revealed improved retention of DOX within the drug-resistant cells when bound on PSX NSs. DOX bound on the surface of PSX NSs, i.e., PSX@DOX, improved, in general, the DOX cytotoxicity in vitro. More importantly, PSX@DOX reduced the growth of DOX-resistant tumors in vivo with 3.5 times better average efficiency than the free drug. Altogether, this paper represents an introduction of a new 2D nanomaterial derived from silicane and pioneers its biomedical application. As advances in the field of material synthesis are rapidly progressing, novel 2D nanomaterials with improved properties are being synthesized and await thorough exploration. Our findings further provide a better understanding of the mechanisms involved in the cancer resistance and can promote the development of a precise cancer therapy.

Links

LM2018129, research and development project
Name: Národní infrastruktura pro biologické a medicínské zobrazování Czech-BioImaging
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1246/2020, interní kód MU
Name: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Acronym: KAVASYKAMO)
Investor: Masaryk University
MUNI/A/1698/2020, interní kód MU
Name: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF)
Investor: Masaryk University
NU21-08-00407, research and development project
Name: Funkční nanoroboti pro navigovanou kombinovanou nádorovou terapii
Investor: Ministry of Health of the CR, Subprogram 1 - standard
ROZV/28/LF17/2020, interní kód MU
Name: Magnetoboti pro fototermální a magnetotermální terapii nádorových onemocnění
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects